Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valproic acid - Cereno Scientific

Next Previous
Drug Profile

Valproic acid - Cereno Scientific

Alternative Names: CS-1

Latest Information Update: 12 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cereno Scientific
  • Class Anti-ischaemics; Antiarrhythmics; Antiepileptic drugs; Antimigraines; Antineoplastics; Antithrombotics; Cardiovascular therapies; Nootropics; Pentanoic acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors; Glutamate decarboxylase stimulants; Histone deacetylase inhibitors; Neurotransmitter modulators; Plasminogen activator inhibitor-1 inhibitors; Plasminogen activators; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pulmonary arterial hypertension
  • Discontinued Stroke; Thrombosis; Venous thromboembolism

Most Recent Events

  • 08 Dec 2025 The US FDA grants clearance to initiate the phase IIb trial of CS1 for the treatment of Pulmonary arterial hypertension (PAH)
  • 08 Dec 2025 Cereno Scientific plans a phase IIb trial for Pulmonary arterial hypertension in the US, the European Union and South America (PO) in the second quarter of 2026
  • 10 Nov 2025 Cereno Scientific completes a Type C meeting with US FDA for Pulmonary arterial hypertension

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top